Photo illustration: Axios Visuals. Photo: Foresite Capital
The Trump administration's health platform is prompting biotech investor Foresite Capital to reevaluate its strategy, CEO Jim Tananbaum tells Axios Pro.
Why it matters: Many investors have been reluctant to speak on the record about President Trump's FDA policies, which frequently run counter to established science.
